Superoxide dismutase liposomal - Apeiron Biologics/Polymun Scientific

Drug Profile

Superoxide dismutase liposomal - Apeiron Biologics/Polymun Scientific

Alternative Names: APN-201; Liposomal recombinant human Cu/Zn-superoxide dismutase; Lipoxysan; rhSOD - Apeiron Biologics/Polymun Scientific

Latest Information Update: 27 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polymun Scientific
  • Developer Apeiron Biologics; Polymun Scientific
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Peyronie's disease
  • No development reported Radiodermatitis

Most Recent Events

  • 27 Jul 2015 No recent reports on development identified - Phase-II for Radiodermatitis (Prevention) in Austria (Topical)
  • 12 Mar 2013 Efficacy and adverse events data from a phase I/II trial in Radiodermatitis (Prevention) released by Apeiron Biologics
  • 23 Jan 2012 Apeiron Biologics initiates enrolment in a phase Ib/II trial for Radiodermatitis (Prevention) in Austria (NCT01513278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top